198 related articles for article (PubMed ID: 37795639)
21. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
[TBL] [Abstract][Full Text] [Related]
22. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
23. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
[TBL] [Abstract][Full Text] [Related]
25. The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines.
Douros JD; Mokrosinski J; Finan B
J Endocrinol; 2024 May; 261(2):. PubMed ID: 38451873
[TBL] [Abstract][Full Text] [Related]
26. The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation.
Estall JL; Koehler JA; Yusta B; Drucker DJ
J Biol Chem; 2005 Jun; 280(23):22124-34. PubMed ID: 15817468
[TBL] [Abstract][Full Text] [Related]
27. Targeting GLP-1 receptor trafficking to improve agonist efficacy.
Jones B; Buenaventura T; Kanda N; Chabosseau P; Owen BM; Scott R; Goldin R; Angkathunyakul N; Corrêa IR; Bosco D; Johnson PR; Piemonti L; Marchetti P; Shapiro AMJ; Cochran BJ; Hanyaloglu AC; Inoue A; Tan T; Rutter GA; Tomas A; Bloom SR
Nat Commun; 2018 Apr; 9(1):1602. PubMed ID: 29686402
[TBL] [Abstract][Full Text] [Related]
28. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic potential of GLP-1 receptor biased agonism.
Jones B
Br J Pharmacol; 2022 Feb; 179(4):492-510. PubMed ID: 33880754
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 receptor action in the vasculature.
Almutairi M; Al Batran R; Ussher JR
Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
[TBL] [Abstract][Full Text] [Related]
31. Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.
Cary BP; Hager MV; Gellman SH
Chembiochem; 2019 Nov; 20(22):2834-2840. PubMed ID: 31172641
[TBL] [Abstract][Full Text] [Related]
32. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
Nakane A; Gotoh Y; Ichihara J; Nagata H
Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
[TBL] [Abstract][Full Text] [Related]
33. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.
Chepurny OG; Matsoukas MT; Liapakis G; Leech CA; Milliken BT; Doyle RP; Holz GG
J Biol Chem; 2019 Mar; 294(10):3514-3531. PubMed ID: 30622136
[TBL] [Abstract][Full Text] [Related]
34. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
35. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
36. Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.
Hager MV; Clydesdale L; Gellman SH; Sexton PM; Wootten D
Biochem Pharmacol; 2017 Jul; 136():99-108. PubMed ID: 28363772
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
38. Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism.
Lei S; Clydesdale L; Dai A; Cai X; Feng Y; Yang D; Liang YL; Koole C; Zhao P; Coudrat T; Christopoulos A; Wang MW; Wootten D; Sexton PM
J Biol Chem; 2018 Jun; 293(24):9370-9387. PubMed ID: 29717000
[TBL] [Abstract][Full Text] [Related]
39. Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects.
Zhang H; Sturchler E; Zhu J; Nieto A; Cistrone PA; Xie J; He L; Yea K; Jones T; Turn R; Di Stefano PS; Griffin PR; Dawson PE; McDonald PH; Lerner RA
Nat Commun; 2015 Dec; 6():8918. PubMed ID: 26621478
[TBL] [Abstract][Full Text] [Related]
40. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
